Literature DB >> 22524471

Effect of parotid gland massage on parotid gland Tc-99m pertechnetate uptake.

Hae Won Kim1, Byeong-Cheol Ahn, Sang-Woo Lee, Jaetae Lee.   

Abstract

BACKGROUND: Salivary dysfunction is the most common side effect associated with (131)I therapy in patients with differentiated thyroid cancer. The purpose of this study was to evaluate the effect of parotid gland (PG) massage on radioisotope accumulation in the salivary gland.
METHODS: Sixty patients were included in this study. Using Tc-99m pertechnetate, two salivary scans were performed in all patients. In 30 patients, PG massage was performed between the two salivary gland scans, whereas in the other 30 patients no massage was performed between the two scans. Total counts of both PGs and accumulation ratios were calculated.
RESULTS: In the patients who received massage, no difference was observed between the mean PG counts of first and second images (8556.9±3333.4 count vs. 8598.3±3341.3 count, p=0.39). In the patients who did not receive massage, the mean PG count on second images was significantly higher than that on first images (8581.2±3618.0 count vs. 9096.4±3654.0 count, p<0.01). Mean accumulation ratio in the patients who received massage was significantly lower than in the patients who did not receive massage (0.5%±3.3% vs. 6.8%±3.8%, p<0.01). Further, among the patients who received massage there was a higher percentage of patients with a negative accumulation ratio than among the patients who did not receive massage (43.3% vs. 0%, p<0.01).
CONCLUSIONS: PG massage can reduce Tc-99m pertechnetate accumulation in the PG, and thus, should be helpful to prevent salivary damage associated with (131)I therapy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22524471      PMCID: PMC3358109          DOI: 10.1089/thy.2011.0188

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  31 in total

Review 1.  Radioactive iodine and the salivary glands.

Authors:  Susan J Mandel; Louis Mandel
Journal:  Thyroid       Date:  2003-03       Impact factor: 6.568

Review 2.  On the mechanism of salivary gland radiosensitivity.

Authors:  Antonius W T Konings; Rob P Coppes; Arjan Vissink
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-07-15       Impact factor: 7.038

Review 3.  Role of nuclear scintigraphy in the characterization and management of the salivary component of Sjögren's syndrome.

Authors:  Frederick B Vivino; George A Hermann
Journal:  Rheum Dis Clin North Am       Date:  2008-11       Impact factor: 2.670

4.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.

Authors:  David S Cooper; Gerard M Doherty; Bryan R Haugen; Bryan R Hauger; Richard T Kloos; Stephanie L Lee; Susan J Mandel; Ernest L Mazzaferri; Bryan McIver; Furio Pacini; Martin Schlumberger; Steven I Sherman; David L Steward; R Michael Tuttle
Journal:  Thyroid       Date:  2009-11       Impact factor: 6.568

5.  The dental safety profile of high-dose radioiodine therapy for thyroid cancer: long-term results of a longitudinal cohort study.

Authors:  Martin A Walter; Christian P Turtschi; Christian Schindler; Peter Minnig; Jan Müller-Brand; Beat Müller
Journal:  J Nucl Med       Date:  2007-09-14       Impact factor: 10.057

6.  Quantitative thyroid scintigraphy for the differentiation of Graves' disease and hyperthyroid autoimmune thyroiditis.

Authors:  C O Sahlmann; U Siefker; K Lehmann; E Harms; M Conrad; J Meller
Journal:  Nuklearmedizin       Date:  2004-08       Impact factor: 1.379

7.  Kinetics of perrhenate uptake and comparative biodistribution of perrhenate, pertechnetate, and iodide by NaI symporter-expressing tissues in vivo.

Authors:  Lionel S Zuckier; Orsolya Dohan; Yi Li; Chee Jen Chang; Nancy Carrasco; Ekaterina Dadachova; Orshi Dohan
Journal:  J Nucl Med       Date:  2004-03       Impact factor: 10.057

8.  Salivary gland protection with sialagogues: a case study.

Authors:  Douglas Van Nostrand; Frank Atkins; Varalakshmi V Bandaru; Shyam P Chennupati; Shari Moreau; Kenneth Burman; Leonard Wartofsky
Journal:  Thyroid       Date:  2009-09       Impact factor: 6.568

9.  The relationship between sialographic images and clinical symptoms of inflammatory parotid gland diseases.

Authors:  Jin-Woo Choi; Sam-Sun Lee; Kyung-Hoe Huh; Won-Jin Yi; Min-Suk Heo; Soon-Chul Choi
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2009-01-20

10.  A comparison between the gastric and salivary concentration of iodide, pertechnetate, and bromide in man.

Authors:  R M Harden; W D Alexander; J Shimmins; D Chisholm
Journal:  Gut       Date:  1969-11       Impact factor: 23.059

View more
  5 in total

1.  Reduction of Salivary Gland Damage During Radioiodine Therapy for Differentiated Thyroid Cancers.

Authors:  Byeong-Cheol Ahn
Journal:  Nucl Med Mol Imaging       Date:  2020-05-12

Review 2.  KSNM60 in Nuclear Endocrinology: from the Beginning to the Future.

Authors:  Chae Moon Hong; Young Jin Jeong; Hae Won Kim; Byeong-Cheol Ahn
Journal:  Nucl Med Mol Imaging       Date:  2022-01-24

3.  Sodium iodide symporter for nuclear molecular imaging and gene therapy: from bedside to bench and back.

Authors:  Byeong-Cheol Ahn
Journal:  Theranostics       Date:  2012-04-11       Impact factor: 11.556

4.  Prevention of salivary gland dysfunction in patients treated with radioiodine for differentiated thyroid cancer: A systematic review of randomized controlled trials.

Authors:  Arunrat Auttara-Atthakorn; Jaruwan Sungmala; Thunyarat Anothaisintawee; Sirimon Reutrakul; Chutintorn Sriphrapradang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-29       Impact factor: 6.055

Review 5.  Clinical Studies of Nonpharmacological Methods to Minimize Salivary Gland Damage after Radioiodine Therapy of Differentiated Thyroid Carcinoma: Systematic Review.

Authors:  Andri Christou; Evridiki Papastavrou; Anastasios Merkouris; Savvas Frangos; Panayiota Tamana; Andreas Charalambous
Journal:  Evid Based Complement Alternat Med       Date:  2016-06-30       Impact factor: 2.629

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.